Stock Events

Stock Events

Edgewise Therapeutics 

$43.07
26
+$1.12+2.67% Friday 20:00
+$1.81+4.2%Friday 23:54After hours

Statistics

Day High
43.16
Day Low
43.06
52W High
48.4
52W Low
13.69
Volume
20,273
Avg. Volume
-
Mkt Cap
4.68B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.53
-0.47
-0.4
-0.34
Expected EPS
-0.53375
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-167.8MNet Income

Analyst Ratings

51.13Average Price Target
The highest estimate is 60.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EWTX. It's not an investment recommendation.
NVIDIA
11
NVDA
Apple
9
AAPL
Microsoft
9
MSFT
Broadcom
9
AVGO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, directly competing in the muscular dystrophy market where Edgewise Therapeutics is also active.
Dyadic International DE
DYAI
Mkt Cap24.6M
Dyadic International, Inc. works on developing and commercializing protein-based therapeutics for diseases, including muscular disorders, which puts them in direct competition with Edgewise Therapeutics' focus.
Silence Therapeutics
SLN
Mkt Cap834.11M
Silence Therapeutics develops gene silencing and RNA interference (RNAi) therapeutics, targeting conditions that overlap with Edgewise Therapeutics' focus areas, including muscular diseases.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics is involved in the discovery and commercialization of orally administered small molecule drugs and gene therapies for muscular dystrophies, competing in the same therapeutic areas as Edgewise Therapeutics.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including therapies for muscular dystrophies, directly competing with Edgewise Therapeutics.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is focused on developing gene-based medicines for serious diseases, including muscular dystrophies, which could compete with Edgewise Therapeutics' gene-targeted therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in developing and commercializing therapies for treating cystic fibrosis and other serious diseases, including a focus on gene editing and therapy that could extend to muscular diseases, indirectly competing with Edgewise Therapeutics.

About

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Show more...
CEO
Kevin Koch
Employees
127
Country
United States
ISIN
US28036F1057

Listings

XNAS
US
EWTX
BOATS
BOATS
EWTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Edgewise Therapeutics stock price today?▼
The current price of EWTX is $43.07 USD — it has increased by +2.67% in the past 24 hours. Watch Edgewise Therapeutics stock price performance more closely on the chart.
What is Edgewise Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Edgewise Therapeutics stocks are traded under the ticker EWTX.
Is Edgewise Therapeutics stock price growing?▼
EWTX stock has risen by +0.72% compared to the previous week, the month change is a -4.27% fall, over the last year Edgewise Therapeutics has showed a +176.62% increase.
What is Edgewise Therapeutics market cap?▼
Today Edgewise Therapeutics has the market capitalization of 4.68B
When is the next Edgewise Therapeutics earnings date?▼
Edgewise Therapeutics is going to release the next earnings report on November 05, 2026.
What were Edgewise Therapeutics earnings last quarter?▼
EWTX earnings for the last quarter are -0.53 USD per share, whereas the estimation was -0.47 USD resulting in a -13.32% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Edgewise Therapeutics revenue for the last year?▼
Edgewise Therapeutics revenue for the last year amounts to 0 USD.
What is Edgewise Therapeutics net income for the last year?▼
EWTX net income for the last year is -167.8M USD.
How many employees does Edgewise Therapeutics have?▼
As of September 05, 2026, the company has 127 employees.
In which sector is Edgewise Therapeutics located?▼
Edgewise Therapeutics operates in the Health & Wellness sector.
When did Edgewise Therapeutics complete a stock split?▼
Edgewise Therapeutics has not had any recent stock splits.
Where is Edgewise Therapeutics headquartered?▼
Edgewise Therapeutics is headquartered in BOULDER, United States.